Follow-Up for MDD and GAD on Citalopram and Aripiprazole
Assess therapeutic response, medication adherence, and adverse effects within 1-2 weeks of any dose adjustment, then biweekly to monthly until symptom remission is achieved. 1
Structured Follow-Up Assessment
Immediate Priorities (Every Visit Until Stable)
Screen for safety concerns first:
- Suicidal ideation or self-harm risk—if present, refer immediately for emergency evaluation 2
- Assess for akathisia, restlessness, or extrapyramidal symptoms from aripiprazole 3
- Monitor for activation symptoms (agitation, nervousness) which occur more frequently in anxious depression patients on SSRIs 4
Symptom Monitoring Schedule
Biweekly to monthly assessments until remission 2:
- Depression severity: Use standardized tools (PHQ-9 or HAM-D) to quantify response
- Anxiety symptoms: Track GAD-specific symptoms separately, as 50-60% of MDD patients have comorbid anxiety 2
- Functional impairment: Assess work, social, and daily functioning using tools like the Sheehan Disability Scale 3
Medication-Specific Monitoring
For citalopram (Celexa):
- Common CNS side effects: drowsiness, nervousness, agitation 2, 4
- These are typically most severe in weeks 1-4 and may be more pronounced with baseline anxious features 4
For aripiprazole (Abilify) augmentation 3:
- Typical dose range: 2-15 mg/day for MDD augmentation
- Dose adjustments should occur at minimum 1-week intervals
- Monitor for akathisia, weight changes, and metabolic effects
- Most side effects are CNS-related (drowsiness, nervousness) 5, 4
Treatment Response Timeline
Evaluate adequacy of response at 6-8 weeks 1:
If inadequate response (less than 50% symptom improvement):
- Consider dose optimization of current regimen first
- Switching strategies: Change to different antidepressant class
- Augmentation strategies: Add bupropion, buspirone, or continue aripiprazole optimization 6
- Consider adding evidence-based psychotherapy (CBT, interpersonal therapy, problem-solving therapy) 7, 6
If adequate response achieved:
- Continue treatment for 9-12 months minimum after recovery 7
- For patients with ≥2 prior episodes, longer maintenance therapy is beneficial 1
- Do not discontinue antidepressants before 9-12 months post-remission 7
Adherence and Tolerability Assessment
At each visit, systematically evaluate 2:
- Medication adherence: Identify barriers (cost, side effects, forgetfulness)
- Side effect burden: Distinguish between tolerable vs. intolerable effects
- Patient satisfaction: With symptom relief and treatment overall
- Referral follow-through: If psychotherapy was recommended, confirm attendance
Common pitfall: Patients with depression often lack motivation to follow through on referrals or comply with treatment—proactive outreach is essential 2
When to Modify Treatment
After 8 weeks of adequate dosing 2:
- If poor symptom reduction despite good compliance, alter the treatment course
- Options include: switching antidepressants, adjusting aripiprazole dose (up to 15 mg/day for MDD), or adding psychotherapy 1, 6
Consider tapering aripiprazole if 2:
- Symptoms are under control
- Primary environmental stressors have resolved
- Patient has maintained stability for appropriate duration
Psychotherapy Integration
Evidence-based options to consider adding or switching to 7, 6:
- Cognitive behavioral therapy (CBT)
- Interpersonal therapy
- Problem-solving therapy
- Behavioral activation
These have comparable efficacy to pharmacotherapy and may be preferred by some patients or combined for enhanced effect in moderate-to-severe depression 6.
Key Clinical Caveats
- Anxious depression predicts higher side effect burden: Patients with baseline GAD-7 ≥10 experience more nervousness and agitation on SSRIs, particularly in the first 2 weeks 4
- Aripiprazole response may occur early: Some patients show improvement within 1-5 weeks, with sustained benefit at lower doses (5-10 mg/day) 5, 8
- Treat depression first: When both MDD and GAD are present, usual practice prioritizes depression treatment, as anxiety often improves concurrently 2